Comparison of 4 consecutive DFCI Consortium Protocols (1981-1995)
| . | Protocols . | |||
|---|---|---|---|---|
| 81-01 . | 85-01 . | 87-01 . | 91-01 . | |
| Years conducted | 1981-1985 | 1985-1987 | 1987-1991 | 1991-1995 |
| Patients, no. | 289 | 220 | 369 | 377 |
| HR, % | 62 | 63 | 62 | 64 |
| Treatment differences | ||||
| Induction | ||||
| Methotrexate | high vs low | low | high vs low | high |
| Asparaginase | none | 1 dose | 1 dose | none |
| Weeks of therapy during intensification | 20 | 20 | 20 | 30 |
| CNS therapy | ||||
| SR, cGy | 1800 | 1800 | no XRT | no XRT (female), 1800 (male) |
| HR, cGy | 2800 | 2400 | 1800 | 1800 |
| Post-remission steroid | prednisone | prednisone | prednisone | dexamethasone |
| Remission death rate, % | 3.5 | 3.6 | 2.0 | 3.2 |
| 5-y ± SE, % | ||||
| EFS | 74 ± 3 | 78 ± 3 | 78 ± 2 | 83 ± 25-150 |
| LFS | 79 ± 3 | 82 ± 3 | 80 ± 2 | 87 ± 25-151 |
| . | Protocols . | |||
|---|---|---|---|---|
| 81-01 . | 85-01 . | 87-01 . | 91-01 . | |
| Years conducted | 1981-1985 | 1985-1987 | 1987-1991 | 1991-1995 |
| Patients, no. | 289 | 220 | 369 | 377 |
| HR, % | 62 | 63 | 62 | 64 |
| Treatment differences | ||||
| Induction | ||||
| Methotrexate | high vs low | low | high vs low | high |
| Asparaginase | none | 1 dose | 1 dose | none |
| Weeks of therapy during intensification | 20 | 20 | 20 | 30 |
| CNS therapy | ||||
| SR, cGy | 1800 | 1800 | no XRT | no XRT (female), 1800 (male) |
| HR, cGy | 2800 | 2400 | 1800 | 1800 |
| Post-remission steroid | prednisone | prednisone | prednisone | dexamethasone |
| Remission death rate, % | 3.5 | 3.6 | 2.0 | 3.2 |
| 5-y ± SE, % | ||||
| EFS | 74 ± 3 | 78 ± 3 | 78 ± 2 | 83 ± 25-150 |
| LFS | 79 ± 3 | 82 ± 3 | 80 ± 2 | 87 ± 25-151 |